Zacks Investment Research Research Analysts Raise Earnings Estimates for ContraFect Corp (CFRX)

ContraFect Corp (NASDAQ:CFRX) – Analysts at Zacks Investment Research raised their FY2018 EPS estimates for ContraFect in a research note issued on Wednesday. Zacks Investment Research analyst D. Bautz now expects that the biotechnology company will post earnings per share of ($0.34) for the year, up from their prior estimate of ($0.41). Zacks Investment Research also issued estimates for ContraFect’s FY2019 earnings at ($0.36) EPS.

How to Become a New Pot Stock Millionaire

ContraFect (NASDAQ:CFRX) opened at $1.86 on Friday. ContraFect has a 1-year low of $0.80 and a 1-year high of $2.40. The company has a market cap of $145.84, a price-to-earnings ratio of -6.20 and a beta of -0.62.

ContraFect (NASDAQ:CFRX) last issued its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.04.

A number of hedge funds and other institutional investors have recently modified their holdings of CFRX. Deutsche Bank AG raised its holdings in ContraFect by 167.2% in the 4th quarter. Deutsche Bank AG now owns 116,224 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 72,732 shares in the last quarter. Renaissance Technologies LLC raised its holdings in ContraFect by 156.6% in the 4th quarter. Renaissance Technologies LLC now owns 194,500 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 118,700 shares in the last quarter. Anson Funds Management LP purchased a new stake in shares of ContraFect in the 4th quarter worth about $301,000. 683 Capital Management LLC purchased a new stake in shares of ContraFect in the 3rd quarter worth about $2,886,000. Finally, Fosun International Ltd purchased a new stake in shares of ContraFect in the 3rd quarter worth about $9,435,000. Institutional investors and hedge funds own 61.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Research Analysts Raise Earnings Estimates for ContraFect Corp (CFRX)” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3294551/zacks-investment-research-research-analysts-raise-earnings-estimates-for-contrafect-corp-cfrx.html.

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Earnings History and Estimates for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Inogen  Expected to Post Quarterly Sales of $62.60 Million
Inogen Expected to Post Quarterly Sales of $62.60 Million
Steem  Trading Up 13.1% Over Last Week
Steem Trading Up 13.1% Over Last Week
BitAsean  Market Capitalization Achieves $88,048.00
BitAsean Market Capitalization Achieves $88,048.00
C R Bard  Earns Coverage Optimism Rating of 0.16
C R Bard Earns Coverage Optimism Rating of 0.16
Mondelez International  Receives Media Sentiment Rating of 0.11
Mondelez International Receives Media Sentiment Rating of 0.11
Somewhat Positive Press Coverage Somewhat Unlikely to Impact Honda Motor  Stock Price
Somewhat Positive Press Coverage Somewhat Unlikely to Impact Honda Motor Stock Price


© 2006-2018 Ticker Report. Google+.